Durable B-Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis.

ABSTRACT:

Objectives

Ocrelizumab (OCR), a humanized anti-CD20 monoclonal antibody, is highly efficient in relapsing-remitting multiple sclerosis (RR-MS). We assessed early cellular B-cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation. This study aims to provide new clues about the mechanisms of action of OCR and about disease pathophysiology.

Methods

Patients with early, treatment-naive, RR-MS were included from 11 centers participating in an ancillary study of the ENSEMBLE trial (NCT03085810) to evaluate the effectiveness and safety of OCR. The phenotypic B-cell immune profile was comprehensively assessed in 18 patients by spectral flow cytometry at baseline, after 1 year of OCR treatment, and compared with 10 healthy vo

SUBMITTER: Garcia A 

PROVIDER: S-EPMC12623837 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature